Litmus email source
Copy source
<!DOCTYPE html> <html xmlns="http://www.w3.org/1999/xhtml" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office"> <head> <title>Novo Nordisk</title> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"> <meta name="viewport" content="width=device-width"> <!--[if gte mso 9]><xml> <o:OfficeDocumentSettings> <o:AllowPNG/> <o:PixelsPerInch>96</o:PixelsPerInch> </o:OfficeDocumentSettings> </xml><![endif]--> <!--[if (gte mso 15)|(IE)]> <style type="text/css"> table { border-collapse: collapse; border-spacing: 0; mso-line-height-rule: exactly; mso-margin-bottom-alt: 0; mso-margin-top-alt: 0; mso-table-lspace: 0pt; mso-table-rspace: 0pt;} td {mso-hyphenate: none;} </style> <![endif]--> <!--[if gte mso 9]> <style> sup, sub { font-size: 100% !important; } </style> <![endif]--> <style type="text/css"> @media screen { @font-face { font-family: 'Noto Sans'; font-style: italic; font-weight: 400; font-display: fallback; src: local('Noto Sans Italic'), local('NotoSans-Italic'), url('https://fonts.gstatic.com/s/notosans/v9/o-0OIpQlx3QUlC5A4PNr4ARCQ_mu72Bi.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: italic; font-weight: 700; font-display: fallback; src: local('Noto Sans Bold Italic'), local('NotoSans-BoldItalic'), url('https://fonts.gstatic.com/s/notosans/v9/o-0TIpQlx3QUlC5A4PNr4Az5ZuyDzW1IPrie.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: normal; font-weight: 400; font-display: fallback; src: local('Noto Sans'), local('NotoSans'), url('https://fonts.gstatic.com/s/notosans/v9/o-0IIpQlx3QUlC5A4PNr5TRASf6M7Q.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: normal; font-weight: 700; font-display: fallback; src: local('Noto Sans Bold'), local('NotoSans-Bold'), url('https://fonts.gstatic.com/s/notosans/v9/o-0NIpQlx3QUlC5A4PNjXhFVZNyBx2pqPA.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } } #outlook a { padding: 0; } .ReadMsgBody { width: 100%; } .ExternalClass { width: 100%; } .ExternalClass, .ExternalClass p, .ExternalClass span, .ExternalClass font, .ExternalClass td, .ExternalClass div { line-height: 100%; } body, table, td, a { -webkit-text-size-adjust: 100%; -ms-text-size-adjust: 100%; } table, td { mso-table-lspace: 0pt; mso-table-rspace: 0pt; } img { -ms-interpolation-mode: bicubic; } body { margin: 0; padding: 0; } img { border: 0; height: auto; line-height: 100%; outline: none; text-decoration: none; } table { border-collapse: collapse !important; } body { height: 100% !important; margin: 0 auto !important; padding: 0; width: 100% !important; } .default-blue-text a { color: #001965; text-decoration: none; } .default-blue-link-text a { color: #025edc; text-decoration: underline; } .pricing-block-text a { color: #025edc; text-decoration: underline; } .pricing-block-text sup { font-size: 70%; line-height: 0; } @media screen and (max-width: 670px) { .mobile-height-auto { height: auto !important; } } @media screen and (max-width: 670px) { .mobile-break { display: block !important; } } @media screen and (max-width: 670px) { table.mobile-hide, td.mobile-hide, img.mobile-hide, .mobile-hide { display: none !important; } } @media screen and (max-width: 670px) { div.mobile-only-content { display: block !important; max-height: none !important; max-width: 100% !important; height: auto !important; width: auto !important; visibility: visible !important; } } @media screen and (max-width: 670px) { .email-container { max-width: 610px !important; width: 100% !important; } } @media screen and (max-width: 670px) { .col-80 { width: 100% !important; } .col-235 { width: 100% !important; } .col-435 { width: 100% !important; } } @media screen and (max-width: 670px) { .mfs-11 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 11px !important; line-height: 1.4; } } @media screen and (max-width: 670px) { .mfs-30 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 30px !important; line-height: 1.2; } } @media screen and (max-width: 670px) { .mlh-34 { line-height: 34px !important; } } @media screen and (max-width: 670px) { .mpt-0 { padding-top: 0px !important; } .mpb-8 { padding-bottom: 8px !important; } .mpb-12 { padding-bottom: 12px !important; } .mpb-20 { padding-bottom: 20px !important; } .mpt-24 { padding-top: 24px !important; } .mpb-24 { padding-bottom: 24px !important; } .mpb-28 { padding-bottom: 28px !important; } .mpt-30 { padding-top: 30px !important; } .mpb-30 { padding-bottom: 30px !important; } } @media screen and (max-width: 670px) { .email-gutter { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-mobile-only { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-15 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-80 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-90 { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-mobile-10 { padding-right: 10px !important; padding-left: 10px !important; } } </style> </head> <body style="background-color: #F6F5FA;"> <center style="width: 100%"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color: #F6F5FA;"> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter-desktop-only" style="padding-left: 30px; padding-right: 30px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="border-bottom: 1px solid #E5E3E6;"> <tr> <td valign="top" class="email-gutter-15" style="padding-bottom: 10px; padding-left: 15px; padding-right: 15px; padding-top: 10px;"> <table cellpadding="0" cellspacing="0" border="0" align="left" width="100%"> <tr> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 10px; font-weight: normal; line-height: 1.4;">$PRE_HEADER$</td> <td align="right" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 10px; font-weight: normal; line-height: 1.4; width: 100px;"><a href="#" target="_blank" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">View online</a></td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter-mobile-10"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" class="mpb-12" style="padding-bottom: 8px; padding-top: 16px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="middle" class="mfs-11" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding: 0 5px 0 0;"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/alhemo.html?tc=em_r42d50z&cc=5003&utm_medium=email&utm_source=iqva&utm_campaign=alhemo_promotional&utm_content=dosing_us26ahm00030&showisi=true" target="_blank" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Important Safety Information</a></td> <td align="center" style="color: #4a4a4a; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4;"> | </td> <td align="center" valign="middle" class="mfs-11" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding: 0 0 0 5px;"><a href="https://www.novo-pi.com/alhemo.pdf?tc=em_r42d50z&cc=5003&utm_medium=email&utm_source=iqva&utm_campaign=alhemo_promotional&utm_content=dosing_us26ahm00030" target="_blank" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Prescribing Information</a></td> </tr> </table> </td> </tr> <tr> <td align="center" style="padding-bottom: 4px;"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/alhemo.html?tc=em_r42d50z&cc=5003&utm_medium=email&utm_source=iqva&utm_campaign=alhemo_promotional&utm_content=dosing_us26ahm00030" target="_blank" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-lab-test-cpd/images/alhemo-logo.png" width="160" height="90" border="0" alt="Logo for Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg" style="display: inline-block;"></a></td> </tr> </table> </td> </tr> <tr> <td align="center" class="email-gutter-80" style="padding-left: 80px; padding-right: 80px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-style: italic; font-weight: normal; line-height: 18px; padding-bottom: 16px;">Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with or without Factor VIII or IX inhibitors.</td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" style="background-color: #3C288B;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="color: #FBB03B; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: bold; line-height: 14px; padding-bottom: 8px; padding-top: 8px;"><a href="https://www.novomedlink.com/account/create.html?tc=em_r42d50z&cc=5003&utm_medium=email&utm_source=iqva&utm_campaign=alhemo_promotional&utm_content=dosing_us26ahm00030" target="_blank" style="color: #FBB03B; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Sign up</a> to stay in the know</td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" height="10" style="height: 10px; line-height: 10px;"> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td class="col-235 mobile-hide" valign="top" style="width: 235px;"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-lab-test-cpd/images/pens-image.png" width="235" height="420" alt="Alhemo Pens" class="mobile-hide" style="display: block;"></td> <td class="col-435" valign="top" style="width: 435px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td class="email-gutter-mobile-only mobile-height-auto mpt-30 mpb-30" valign="middle" height="140" style="background-color: #362380; padding-left: 0; padding-right: 0;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td width="12" style="width: 12px;" class="mobile-hide"> </td> <td align="left" class="mfs-30 mlh-34" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 36px; font-weight: bold; line-height: 40px; text-transform: uppercase;">Discover the Alhemo<sup style="font-size: 60%; line-height: 1;">®</sup> approach<sup style="font-size: 60%; line-height: 1;">1</sup></td> <td width="15" style="width: 15px;" class="mobile-hide"> </td> </tr> </table> </td> </tr> <tr> <td class="email-gutter-mobile-only" style="padding-left: 0; padding-right: 0; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="12" style="width: 12px;" class="mobile-hide"> </td> <td align="left" style="color: #5433B0; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 22px; padding-bottom: 12px;">Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> is TFPI antagonist that offers an FDA-authorized test (Concizumab ELISA) to measure plasma drug levels for individualized dose optimization.</td> <td width="30" style="width: 30px;" class="mobile-hide"> </td> </tr> <tr> <td width="12" style="width: 12px;" class="mobile-hide"> </td> <td align="left" style="color: #5433B0; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 16px;">This blood test measures concizumab-mtci plasma levels to assess whether levels are in the <b>therapeutic range</b>.<sup style="font-size: 70%; line-height: 1;">a</sup> Along with weight-based dosing, this FDA-authorized test allows for <b>treatment individualization</b> to <b>optimize dosing</b>.</td> <td width="30" style="width: 30px;" class="mobile-hide"> </td> </tr> </table> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-lab-test-cpd/images/pens-image-mobile.png" width="200" height="410" alt="Alhemo Pens" style="display: block;"></td> </tr> </table> </div> <!--<![endif]--> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter mpb-28" style="padding-bottom: 40px; padding-left: 30px; padding-right: 30px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" class="mpb-24" style="padding-bottom: 40px;"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/alhemo/dosing-administration/dosing-with-the-alhemo-pen.html?tc=em_r42d50z&cc=5003&utm_medium=email&utm_source=iqva&utm_campaign=alhemo_promotional&utm_content=dosing_us26ahm00030" target="_blank" style="background-color: #fbb03b; border-radius: 50px; color: #001965; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; mso-padding-alt: 0; padding-bottom: 12px; padding-left: 25px; padding-right: 25px; padding-top: 12px; text-decoration: none; text-underline-color: #fbb03b;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Explore personalized dosing<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0" width="210" style="width: 210px;"> <tr> <td height="12" style="height: 12px; line-height: 12px; border-bottom: 2px solid #FBB03B"> </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #5433B0; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 20px; font-weight: bold; line-height: 24px; padding-bottom: 20px; padding-top: 20px;">Recommended Dosing Regimen:</td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" valign="top" width="72" style="width: 72px;" class="mobile-hide"> <table border="0" cellpadding="0" cellspacing="0" width="100%" class="mobile-hide"> <tr> <td align="left" valign="top" style="color: #5433B0; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 18px; font-weight: bold; line-height: 24px; padding-bottom: 28px;">DAY 1</td> </tr> <tr> <td align="left" valign="top" style="color: #5433B0; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 18px; font-weight: bold; line-height: 24px; padding-bottom: 38px;">DAY 2+</td> </tr> <tr> <td align="left" valign="top" style="color: #5433B0; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 18px; font-weight: bold; line-height: 24px; padding-bottom: 24px;">DAY 28</td> </tr> </table> </td> <td align="left" valign="top" width="44" style="width: 44px;"> <img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-lab-test-cpd/images/days-graphic.png" width="30" height="266" alt class="mobile-hide" style="display: block;"> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-lab-test-cpd/images/days-graphic-mobile.png" width="44" height="400" alt style="display: block;"> </div> <!--<![endif]--> </td> <td align="left" valign="top"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" valign="top" class="mpt-0 mpb-24" style="padding-bottom: 30px; padding-top: 4px;"> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" valign="top" style="color: #5433B0; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 18px; font-weight: bold; line-height: 24px; padding-bottom: 2px;">DAY 1</td> </tr> </table> </div> <!--<![endif]--> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px;">One-time loading dose is <span style="white-space: nowrap;">1 mg/kg</span></td> </tr> </table> </td> </tr> <tr> <td align="left" valign="top" class="mpb-20" style="padding-bottom: 30px;"> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" valign="top" style="color: #5433B0; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 18px; font-weight: bold; line-height: 24px; padding-bottom: 2px;">DAY 2+</td> </tr> </table> </div> <!--<![endif]--> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px;">Once-daily dose is <span style="white-space: nowrap;">0.2 mg/kg</span> (until optimized dose determined)</td> </tr> </table> </td> </tr> <tr> <td align="left" valign="top" style="padding-bottom: 8px;"> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" valign="top" style="color: #5433B0; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 18px; font-weight: bold; line-height: 24px; padding-bottom: 2px;">DAY 28</td> </tr> </table> </div> <!--<![endif]--> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px;">Administer Concizumab ELISA <span class="mobile-break" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 1.4;">(4 weeks after initiation of Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup>)</span></td> </tr> </table> </td> </tr> <tr> <td align="left" style="padding-bottom: 8px;"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tr> <td width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; width: 20px;" align="center" valign="top">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px;">Advise patients to administer Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> after ELISA blood draw on day of the test</td> </tr> <tr> <td width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; width: 20px;" align="center" valign="top">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px;">Results reported within 10 working days</td> </tr> </table> </td> </tr> <tr> <td align="left" valign="top" class="mpb-8" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 32px;">Personalized dose adjustment, if needed, will be confirmed no later than 8 weeks after treatment initiation.</td> </tr> </table> </td> <td align="left" valign="top" width="30" style="width: 30px;" class="mobile-hide"> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" class="mpt-24"> <table border="0" cellpadding="0" cellspacing="0" width="210" style="width: 210px;"> <tr> <td height="12" style="height: 12px; line-height: 12px; border-bottom: 2px solid #FBB03B"> </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #5433B0; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 20px; font-weight: bold; line-height: 24px; padding-bottom: 12px; padding-top: 16px;">When should patients be tested?</td> </tr> <tr> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 12px;">Tests should be taken at routine clinical follow-ups, provided the patient has been on the same maintenance dose for 8 weeks of treatment to ensure steady-state plasma concentration.<sup style="font-size: 70%; line-height: 1;">b</sup></td> </tr> <tr> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 30px;">Adherence to daily dosing of Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> is important to maintain protection against bleeding. This is especially important during the initial 4 weeks of treatment to ensure a correct maintenance dose is established.</td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px; padding-bottom: 12px;">ELISA=Enzyme-Linked Immunosorbent Assay; TFPI=tissue factor pathway inhibitor.</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px;"><sup style="font-size: 70%; line-height: 1;">a</sup>Once the concizumab-mtci concentration result is available, individualize the maintenance dose of Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> no later than 8 weeks after initiation of treatment, based on the following concizumab-mtci plasma concentrations:</td> </tr> <tr> <td align="left" style="padding-bottom: 2px; padding-top: 2px;"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tr> <td width="16" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px; width: 16px;" align="center" valign="top">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px;"><span class="default-blue-text">Less than <span style="white-space: nowrap;">200 ng/mL:</span> adjust to a once daily dose of <span style="white-space: nowrap;">0.25 mg/kg</span></span></td> </tr> <tr> <td width="16" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px; width: 16px;" align="center" valign="top">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px;"><span class="default-blue-text">200 to <span style="white-space: nowrap;">4,000 ng/mL:</span> continue once daily dose of <span style="white-space: nowrap;">0.2 mg/kg</span></span></td> </tr> <tr> <td width="16" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px; width: 16px;" align="center" valign="top">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px;"><span class="default-blue-text">Greater than <span style="white-space: nowrap;">4,000 ng/mL:</span> adjust to a once daily dose of <span style="white-space: nowrap;">0.15 mg/kg</span></span></td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px;"><sup style="font-size: 70%; line-height: 1;">b</sup>If concizumab-mtci plasma concentration remains below <span style="white-space: nowrap;">200 ng/mL</span> at two consecutive measurements, evaluate the benefits of continued Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> treatment versus the potential risk of bleeding events, and consider alternative therapies, if available.</td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter mpb-20" style="background-color: #F6F5FA; padding-bottom: 28px; padding-left: 30px; padding-right: 30px; padding-top: 32px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 26px; padding-bottom: 20px;">Important Safety Information</td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 12px;">Contraindications</td> </tr> <tr> <td align="left" style="padding-bottom: 20px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;">•</td> <td width="5"> </td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;">Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> is contraindicated in patients with a history of known serious hypersensitivity to Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> or its ingredients</td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 12px;">Warnings and Precautions</td> </tr> <tr> <td align="left" style="padding-bottom: 16px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;">•</td> <td width="5"> </td> <td align="left"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"><b>Thromboembolic Events (TEs):</b> Venous and arterial TEs were reported in 1.9% of patients (6/320) who also had multiple risk factors, including the use of high doses or prolonged treatment with factor product or bypassing agent (2 of 6 patients). Risk factors for TEs may also include conditions in which tissue factor is overexpressed (eg, atherosclerotic disease, crush injury, cancer, disseminated intravascular coagulation, thrombotic microangiopathy, or septicemia). Inform patients about and monitor them for signs and symptoms of TEs. In case of suspicion of TEs, discontinue Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> and initiate further investigations and management strategies</td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 1.4; padding-bottom: 16px;">Please <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/alhemo.html?showisi=true&tc=em_r42d50z&cc=5003&utm_medium=email&utm_source=iqva&utm_campaign=alhemo_promotional&utm_content=dosing_us26ahm00030" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> or scroll below for additional Important Safety Information.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #001965; width: 670px;"> <tr> <td align="center" class="email-gutter-90" style="padding-bottom: 36px; padding-left: 90px; padding-right: 90px; padding-top: 36px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 20px; font-weight: bold; line-height: 28px; padding-bottom: 12px;">Have questions? Novo Nordisk is here to help.</td> </tr> <tr> <td align="center" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 24px;">Connect with a Novo Nordisk Rare Blood Therapy Manager in your area. They can help you with:</td> </tr> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td width="30" style="padding-bottom: 8px; width: 30px;" align="left" valign="middle"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-lab-test-cpd/images/icon-checkmark.png" width="20" height="20" alt style="display: block;"></td> <td align="left" valign="middle" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 8px;">Clinical product information</td> </tr> <tr> <td width="30" style="padding-bottom: 8px; width: 30px;" align="left" valign="middle"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-lab-test-cpd/images/icon-checkmark.png" width="20" height="20" alt style="display: block;"></td> <td align="left" valign="middle" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 8px;">Rare bleeding education for patients</td> </tr> <tr> <td width="30" style="padding-bottom: 8px; width: 30px;" align="left" valign="middle"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-lab-test-cpd/images/icon-checkmark.png" width="20" height="20" alt style="display: block;"></td> <td align="left" valign="middle" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 8px;">Resources for starting treatment</td> </tr> <tr> <td width="30" style="padding-bottom: 8px; width: 30px;" align="left" valign="middle"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-lab-test-cpd/images/icon-checkmark.png" width="20" height="20" alt style="display: block;"></td> <td align="left" valign="middle" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 8px;">General questions & inquiries</td> </tr> </table> </td> </tr> <tr> <td align="center" style="padding-top: 20px;"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/resources/novonordisk-representative.html?tc=em_r42d50z&cc=5003&utm_medium=email&utm_source=iqva&utm_campaign=alhemo_promotional&utm_content=dosing_us26ahm00030" target="_blank" style="background-color: #ffffff; border-radius: 40px; color: #001965; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 16px; mso-padding-alt: 0; padding-bottom: 10px; padding-left: 30px; padding-right: 30px; padding-top: 10px; text-decoration: none; text-underline-color: #ffffff;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Contact your rep<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" height="10" style="height: 10px; line-height: 10px; background-color: #ffffff;"> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="background-color: #F6F5FA; padding-bottom: 28px; padding-left: 30px; padding-right: 30px; padding-top: 32px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 26px; padding-bottom: 16px;">Indications and Usage for Alhemo<sup style="font-size: 60%; line-height: 1;">®</sup></td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; padding-bottom: 28px;">Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with or without Factor VIII or IX inhibitors.</td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 26px; padding-bottom: 20px;">Important Safety Information (cont’d)</td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 12px;">Warnings and Precautions (cont'd)</td> </tr> <tr> <td align="left" style="padding-bottom: 20px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; width: 20px;">•</td> <td width="5" style="width: 5px;"> </td> <td align="left"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"><b>Hypersensitivity Reactions:</b> Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> is contraindicated in patients with a history of known serious hypersensitivity to Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> or its ingredients. Hypersensitivity reactions, including erythema, rash, pruritus, and abdominal pain, have occurred in patients treated with Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup>. One patient (<1%) experienced anaphylaxis, which resolved after treatment with antihistamines and corticosteroids. Instruct patients of the signs of acute hypersensitivity reactions and to contact their healthcare provider for mild reactions and to seek urgent medical attention for moderate to severe reactions. Discontinue Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> if severe hypersensitivity symptoms occur and initiate medical management</td> </tr> </table> </td> </tr> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; width: 20px;">•</td> <td width="5" style="width: 5px;"> </td> <td align="left"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"><b>Increased Laboratory Values of Fibrin D-dimer and Prothrombin Fragment 1.2:</b> Increased levels of fibrin D-dimer and prothrombin fragment 1.2 were seen in 29 (9.1%) and 26 (8.1%) patients, respectively, which is positively correlated with the plasma concentration of concizumab-mtci, indicating a hemostatic effect. For patients taking Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup>, these coagulation biomarkers may not be reliable predictive markers for clinical decision-making with suspicion of thrombosis, such as deep vein thrombosis and pulmonary embolism</td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 1.4; padding-bottom: 12px;">Adverse Reactions</td> </tr> <tr> <td align="left" style="padding-bottom: 20px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; width: 20px;">•</td> <td width="5" style="width: 5px;"> </td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;">The most frequently reported adverse reactions (≥5%) were injection site reactions, headache, and urticaria</td> </tr> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; width: 20px;">•</td> <td width="5" style="width: 5px;"> </td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;">Serious adverse reactions were reported in 6.1% of patients with inhibitors who received Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup>. Permanent discontinuation of Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> occurred in 1 patient due to a renal infarct and dosage interruptions of Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> occurred in 1 patient (3%) and was a hypersensitivity reaction</td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 1.4; padding-bottom: 12px;">Drug Interactions</td> </tr> <tr> <td align="left" style="padding-bottom: 20px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; width: 20px;">•</td> <td width="5" style="width: 5px;"> </td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"><b>Breakthrough Bleeding Treatment:</b> Take appropriate precautions when treating breakthrough bleeding events in patients receiving Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> prophylaxis and FVIII or FIX or a bypassing agent (eg, rFVIIa or aPCC). For mild and moderate bleeds, the lowest approved dose in the approved product labeling is recommended. For aPCC, a maximum dose of 100 units/kg within 24 hours is recommended. For severe bleeds, follow the dosing instructions in the approved labeling based on clinical judgment</td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 1.4; padding-bottom: 12px;">Please <a href="https://www.novo-pi.com/alhemo.pdf?tc=em_r42d50z&cc=5003&utm_medium=email&utm_source=iqva&utm_campaign=alhemo_promotional&utm_content=dosing_us26ahm00030" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> for Prescribing Information.</td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="left" class="email-gutter" style="background-color: #F6F5FA; padding-bottom: 16px; padding-left: 30px; padding-right: 30px;"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tr> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding-bottom: 12px;"><b>Reference:</b></td> </tr> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">1.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">Alhemo [package insert]. Plainsboro, NJ: Novo Nordisk Inc.</span></td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="background-color: #F6F5FA; padding-bottom: 20px; padding-left: 30px; padding-right: 30px; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td valign="top"> <table cellpadding="0" cellspacing="0" border="0" width="100%" style="border-top: 1px solid #979797"> <!-- Pricing Block Start --> <tr> <td align="left" class="pricing-block-text" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-style: italic; font-weight: bold; line-height: 18px; padding-bottom: 20px; padding-top: 25px;"> Please click on the link to see WAC pricing for the product mentioned above: <a href="https://www.novopricing.com/alhemo.html?tc=em_r42d50z&cc=5003&utm_medium=email&utm_source=iqva&utm_campaign=alhemo_promotional&utm_content=dosing_us26ahm00030" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;" target="_blank">Product Pricing</a>. </td> </tr> <!--Pricing Block End --> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">Please do not respond to this email. If you would like to contact us, please <a href="https://www.novonordisk-us.com/contact-us.html?tc=em_r42d50z&cc=5003&utm_medium=email&utm_source=iqva&utm_campaign=alhemo_promotional&utm_content=dosing_us26ahm00030" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> or call <span class="default-blue-link-text" style="white-space: nowrap;">1-800-727-6500</span>.</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: bold; line-height: 16px; padding-top: 15px;">UNSUBSCRIBE NOTICE</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">If you no longer want to receive communications from Novo Nordisk, <a href="#" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> to unsubscribe. You also may call us at <span class="default-blue-link-text" style="white-space: nowrap;">1-877-744-2579</span> or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our <a href="https://www.novonordisk-us.com/privacy-notice.html?tc=em_r42d50z&cc=5003&utm_medium=email&utm_source=iqva&utm_campaign=alhemo_promotional&utm_content=dosing_us26ahm00030" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Privacy Statement</a>.</span></td> </tr> </table> </td> </tr> <tr> <td valign="bottom" style="padding-bottom: 20px; padding-top: 20px;"> <table cellpadding="0" cellspacing="0" border="0" align="left" width="100%"> <tr> <td align="left" valign="bottom" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> is a registered trademark of Novo Nordisk Health Care AG.<br>novoMEDLINK™ is a trademark of Novo Nordisk A/S.<br>Novo Nordisk is a registered trademark of Novo Nordisk A/S.<br>© 2026 Novo Nordisk All rights reserved. <span style="white-space: nowrap;">US26AHM00030</span> <span style="white-space: nowrap;">May 2026</span></span></td> <td align="right" valign="bottom" class="col-80 mobile-hide" style="width: 80px;"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-lab-test-cpd/images/logo-novo-nordisk.png" width="75" height="55" alt="Novo Nordisk logo." style="display: block;"></td> </tr> </table> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" valign="top" style="padding-top: 20px;"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-lab-test-cpd/images/logo-novo-nordisk.png" width="75" height="55" alt="Novo Nordisk logo." style="display: block;"></td> </tr> </table> </div> <!--<![endif]--> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </center> </body> </html>